Overview 2003, 2004:
cash on hand $8.9 Million Aug 2003 (2-3 years at current burn)
13 new clinical trials commenced in 2003
30 total trials in the field of which we pay only 20%
Currently 4 products are in the pipeline.
They should hit the market at the rate of 1 pipe per year in this order:
CH123/ D'tect
ColorectAlert
LungAlert
BreastAlert
CH123 is 3 products: Tape Test, Wallet Test, Lab test attacking 6 markets:
Physicians offices, Insurance testing, Occupational Health, Home, Co- Promotion, Pharmacies
Completed Milestones by timeline:
CH123: Pivotal trials commence November 1997
ColorectAlert: IMI licences test for detection of early stage colorectal
cancer May 1998
ColorectAlert: IMI files patent application for colorectal cancer detection
test January 1999
LungAlert: IMI files patent application for lung cancer detection test
January 1999
ColorectAlert: Announced May 2000, clinically more accurate than fecal
occult blood testing (FOBT)
CH123: January 29, 2001, Canadian marketing clearance
LungAlert: May 2001 American Thoracic Society, 1st and only early stage test
CH123: June 11, 2001 FDA submission
CH123: July 10, 2001 DCL agrees to make CH123
CH123: September 5, 2001 SG Cowen Securities hired
CH123: October 29, 2001 resubmission to FDA, shares tank to $3.00
CH123: February 25, 2002 Multi-Ethnic Study of Atherosclerosis (MESA 6500 souls)
CH123: April 8, 2002 Sprecher breakthrough at American Heart Association
ColorectAlert: April 15, 2002 ColorectAlert beats FOBT financially
CH123: May 10, 2002 McNeil CDN partnership announced
CH123: June 2002 American Journal of Cardiology paper, Mancini
CH123: June 24, 2002 FDA approval
CH123: Sept. 2002 European approval
CH123 @ home: Oct Q4 2002 Unveiling of 2 new modified home tests
CH123: Oct. 28th 2002 McNeil demos 123 at the Canadian Cardiovascular Congress, Edmonton
CH123: December 2002 signs agreement with McNeil to expand US marketing to the insurance industry, no FDA required
CH123: Feb 27th 2003 Revenue commences with Milestone Payment $100,000
CH123: June 2003 Australian Approval
CH123: June 2003 Found to be reliable and harmless in testing Pediatric cholesterol
D-TECT: Feb 27th 2003 new Coronary Heart Disease Predictor announced
SEC Approval: March 12th 2003 clears IMI for a US listing
American Association for Cancer Research to publish Cancer Suite
Papers, Toronto meeting cancelled due to SARS Apr. 2, 2003
ColorectAlert Trial results announced Apr. 5, 2003 detected 54% early stage
colon cancer, 85% accurate clearing non cancer patients
LungAlert: Q2 2003, Japanese trial with major Japanese Partner commences
LungAlert: Trial results announced Apr. 5, 2003 detected 57% early stage
lung cancer, only 10% false positives
BreastAlert Apr 03 preliminary trial results encouraging
John Hopkins Aug 03; Skin cholesterol is more strongly associated with Arteiosclerosis than blood tests
AtheroGenics Aug 03. a $40-million Phase III trial to test 4,000 heart patients uses CH123
Amex Sept 19 2003: IMI begins trading on the American Stock Exchange symbol IME
Milestones yet to come with approximate timing:
CH123: ISO certification Q4 2003
CH123: Japanese Approval Process completing Q4 2003
CH123: Revenue stream commences Q4 2003
CH123: Announcement of World Wide and or US Partners 2004
D-TECT: McNeil to launch in multiple markets 2004
ColorectAlert: Canadian Approval 2004
ColorectAlert: FDA trials commence 2004
LungAlert: Canadian Approval 2004
LungAlert: FDA trials commence 2004
BreastAlert: expanded trials 2003 -2004
US and EU Development Partners on the Cancer Suite 2004
stockhouse.com |
